Carbapenem-Based Antibiotics Market Size | Report 2021, 2028
Se espera que el tamaño del mercado de antibióticos a base de carbapenems crezca de 3.964,57 millones de dólares en 2021 a 5.346,62 millones de dólares en 2028; Se estima que crecerá a una tasa compuesta anual del 4,4% durante 2021-2028.carbapenem-based antibiotics market size is expected to grow from US$ 3,964.57 million in 2021 to US$ 5,346.62 million by 2028; it is estimated to grow at a CAGR of 4.4% during 2021-2028.
Los carbapenémicos son un tipo de antibióticos β-lactámicos atípicos que tienen una actividad antibacteriana más amplia. Los antibióticos a base de carbapenems pueden cubrir muchas bacterias aeróbicas y anaeróbicas grampositivas y gramnegativas. Además, los antibióticos a base de carbapenems son estables frente a la mayoría de las β-lactamasas. Por lo tanto, están indicados como monoterapia empírica para diversas afecciones graves, como infecciones neutropénicas e infecciones intraabdominales.
La creciente prevalencia de infecciones bacterianas gramnegativas y la creciente producción de medicamentos genéricos impulsan el crecimiento del mercado de antibióticos basados en carbapenems . Sin embargo, el tedioso y costoso proceso de desarrollo de antibióticos frena el crecimiento del mercado.
Personalice la investigación para adaptarla a sus necesidades
Podemos optimizar y adaptar el análisis y el alcance que no se cumplen a través de nuestras ofertas estándar. Esta flexibilidad le ayudará a obtener la información exacta que necesita para la planificación y la toma de decisiones de su negocio.
Mercado de antibióticos a base de carbapenems: Antibiotics Market: ideas estratégicas
CAGR (2021 - 2028)4,4%- Tamaño del mercado 2021
US$ 3,96 mil millones - Tamaño del mercado 2028
US$ 5,35 mil millones
Dinámica del mercado
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
- XXXXXXX
Jugadores claves . Jugadores principales
- Pfizer Inc.
- Salvador Lifetec
- Sumitomo Dainippon Pharma Co., Ltd.
- Merck & Co., Inc.
- Gland Pharma Limited
- Aurobindo Pharma Ltd
- Daewoong Pharmaceutical Co., Ltd,
- Iterum Therapeutics plc
- ACS Dobfar SpA
Panorama regional
- América del norte
- Europa
- Asia-Pacífico
- América del Sur y Central
- Medio Oriente y África
Segmentación de mercado
- meropenem
- doripenem
- imipenem
- tebipenem
- Otros
- Meningitis bacterial
- Infecciones pélvicas agudas
- Infecciones del tracto respiratorio
- Infecciones intraabdominales
- Infecciones del tracto urinario
- Otros
- Farmacias minoristas
- Farmacias en línea
- Farmacias Hospitalarias
- El PDF de muestra muestra la estructura del contenido y la naturaleza de la información con análisis cualitativo y cuantitativo.
Perspectivas del mercado
: aumento de la prevalencia de infecciones bacterianas gramnegativas
Las infecciones bacterianas gramnegativas, como la infección del tracto urinario (ITU), la neumonía, las infecciones del torrente sanguíneo, las infecciones de la herida o del sitio quirúrgico y la meningitis, son comúnmente adquiridas por los pacientes durante su estadía en el hospital. Estas infecciones se conocen generalmente como infecciones adquiridas en hospitales (HAI). Infecciones como ITU y neumonía son comunes en pacientes ingresados en unidades de cuidados intensivos. Según la Red Nacional de Seguridad de la Atención Médica de EE. UU., el 30 % de las HAI son causadas por bacterias gramnegativas, aproximadamente el 45 % se deben a infecciones urinarias y aproximadamente el 47 % se deben a neumonía asociada a ventiladores (NAV). La prevalencia de enfermedades infecciosas causadas por bacterias gramnegativas está aumentando rápidamente.
Además, las infecciones por bacterias gramnegativas son resistentes a múltiples fármacos y han desarrollado una mayor resistencia a los antibióticos disponibles. La resistencia a los antimicrobianos (RAM) se ha convertido en una amenaza global para la medicina moderna. Por lo tanto, se requiere un seguimiento constante de las tendencias emergentes para los aislados clínicos. Un grupo de investigadores de Letonia, Europa, ha estudiado la progresión de la resistencia a los antimicrobianos en diferentes bacterias gramnegativas. Según el artículo de investigación publicado por ellos en la revista MDPI en junio de 2021, los antibióticos a base de carbapenem, como Meropenem y Ertapenem, fueron los más eficaces contra las bacterias gramnegativas, mostrando tasas de resistencia del 3% y el 5,4%, respectivamente. Estos antibióticos son mundialmente aceptados como tratamiento para las bacterias gramnegativas. Por tanto, se estima que es probable que la alta demanda de antibióticos a base de carbapenems continúe en los próximos años.
Según los Centros para el Control y la Prevención de Enfermedades (CDC), la pandemia de COVID-19 provocó un aumento de los casos de HAI en 2020. Las admisiones hospitalarias han aumentado a nivel mundial, lo que ha aumentado el riesgo de NAV como infección secundaria para los pacientes con COVID-19. . Esto ha dado lugar a un aumento de la demanda de antibióticos a base de carbapenems, lo que está ayudando significativamente al mercado.
Información basada en tipos
El mercado de antibióticos a base de carbapenem, por tipo, se segmenta en meropenem, doripenem, imipenem, tebipenem y otros. El segmento de otros tuvo la mayor participación del mercado de antibióticos a base de carbapenems en 2021, y se prevé que registre la CAGR más alta del mercado durante el período de pronóstico. Es probable que los crecientes desarrollos de antibióticos a base de carbapenems impulsen el crecimiento del mercado en el futuro.
Perspectivas basadas en indicaciones
Por indicación, el mercado de antibióticos a base de carbapenems se segmenta en meningitis bacteriana, infecciones pélvicas agudas, infecciones del tracto respiratorio , infecciones intraabdominales, infecciones del tracto urinario y otras. El segmento de otros tuvo la mayor participación del mercado de antibióticos a base de carbapenems en 2021, y se estima que registrará la CAGR más alta del mercado durante el período de pronóstico. La incertidumbre de las infecciones bacterianas impulsa la demanda de antibióticos a base de carbapenems, que se espera que impulse el crecimiento del mercado en los próximos años.
Alcance del informe de mercado de Antibióticos a base de carbapenems
Atributo del informe | Detalles |
---|---|
Tamaño del mercado en 2021 | 3,96 mil millones de dólares |
Tamaño del mercado para 2028 | 5,35 mil millones de dólares |
CAGR global (2021 - 2028) | 4,4% |
Información histórica | 2019-2020 |
Período de pronóstico | 2022-2028 |
Segmentos cubiertos | Por tipo
|
Regiones y países cubiertos | América del norte
|
Líderes del mercado y perfiles clave de empresas |
|
- El PDF de muestra muestra la estructura del contenido y la naturaleza de la información con análisis cualitativo y cuantitativo.
Información basada en el canal de distribución
Por canal de distribución, el mercado de antibióticos a base de carbapenems se segmenta en farmacias minoristas, farmacias en línea y farmacias hospitalarias. El segmento de farmacias hospitalarias tuvo la mayor participación en el mercado de antibióticos a base de carbapenems en 2021, y se estima que registrará la CAGR más alta del mercado durante el período de pronóstico.
Las empresas suelen adoptar estrategias orgánicas, como el lanzamiento de nuevos productos, para ampliar sus carteras de productos en el mercado. Además, las empresas han implementado diversas estrategias inorgánicas, como fusiones, adquisiciones y asociaciones. Por ejemplo, en mayo de 2021, Gland Pharma Limited, en asociación con Dr Reddy's Laboratories Ltd, lanzó Ertapenem inyectable, 1 g/vial, un equivalente terapéutico a la versión genérica de INVANZ (ertapenem inyectable) 1 g/vial, que es aprobado por la Administración de Medicamentos y Alimentos de EE. UU. (USFDA).
Perfiles de empresa
- Pfizer Inc.
- Salvador Lifetec
- Sumitomo Dainippon Pharma Co., Ltd.
- Merck & Co., Inc.
- Gland Pharma Limited
- Aurobindo Pharma Ltd
- DAEWOONG FARMACÉUTICA CO., LTD
- Iterum Therapeutics plc
- ACS Dobfar SpA
- Spero Terapéutica
Carbapenem-Based Antibiotics Market Report Scope
Report Attribute | Details |
---|---|
Market size in | US$ 3.96 Billion |
Market Size by | US$ 5.35 Billion |
Global CAGR | 4.4% |
Historical Data | 2019-2020 |
Forecast period | 2022-2028 |
Segments Covered |
By Tipo
|
Regions and Countries Covered |
América del Norte
|
Market leaders and key company profiles |
|
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The carbapenem-based antibiotics market is analyzed in the basis of type, indication, and distribution channel. Based on type, is segmented into meropenem, doripenem, imipenem, tebipenem, and others. The others segment held the largest share of the market, and it is anticipated to register the highest CAGR. Based indication, the market is segmented as bacterial meningitis, acute pelvic infections, respiratory tract infections, intra-abdominal infections, urinary tract infections, and others. The others segment held the largest share of the market, and it is estimated to register the highest CAGR. And based on distribution channel, the market is divided into retail pharmacies, online pharmacies, and hospital pharmacies. The hospital pharmacies segment held the largest share of the market, and it is estimated to register the highest CAGR.
The carbapenem-based antibiotics market majorly consists of the players such as Pfizer Inc.; Savior Lifetec; Sumitomo Dainippon Pharma Co., Ltd.; Merck & Co., Inc.; Gland Pharma Limited; Aurobindo Pharma Ltd; Daewoong Pharmaceutical Co.,Ltd; Iterum Therapeutics plc; ACS Dobfar S.p.A, and Spero Therapeutics among others.
Carbapenems are type of atypical β-lactam antibiotics that have wider antibacterial activity. Carbapenem-based antibiotics can cover many gram-positive, gram-negative aerobic, anaerobic bacteria. Additionally, carbapenem-based antibiotics are stable to most β-lactamases and hence, are indicated as empiric monotherapy for various serious conditions such as neutropenic infections and intra-abdominal infections.
The factors that are driving the growth of market are growing rising prevalence of gram-negative bacterial infections and increasing production of generic drugs fuel the growth of the market. However, the tedious and expensive process of antibiotic development, as well as approval, is the major factor hindering the market growth.
The List of Companies - Carbapenem Based Antibiotics Market
- Pfizer Inc.
- Savior Lifetec
- Sumitomo Dainippon Pharma Co., Ltd.
- Merck & Co., Inc.
- Gland Pharma Limited
- Aurobindo Pharma Ltd
- Daewoong Pharmaceutical Co.,Ltd,
- Iterum Therapeutics plc
- ACS Dobfar S.p.A
- Spero Therapeutics
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.